Walvax Biotechnology Co., Ltd.
300142
Rang in Aktien
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Aktienkurs
$1.87
Marktkapitalisierung
$2.98B
Veränderung (1 Tag)
-3.71%
Veränderung (1 Jahr)
14.73%
Land
CN
Handel Walvax Biotechnology Co., Ltd. (300142)
Kategorie
Healthcare
Operative Marge für Walvax Biotechnology Co., Ltd. (300142)
Operative Marge zum October 2026 TTM: 6.19%
Laut den neuesten Finanzberichten und dem Aktienkurs von Walvax Biotechnology Co., Ltd. beträgt die aktuelle operative Marge (TTM) 6.19%. Am Ende des Jahres 2024 lag die operative Marge bei 3.43%.
Historie der operativen Marge von Walvax Biotechnology Co., Ltd. von 2007 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 6.19% | 113.45% |
| 2025 | 2.90% | -15.45% |
| 2024 | 3.43% | -77.01% |
| 2023 | 14.92% | -30.99% |
| 2022 | 21.62% | 5.41% |
| 2021 | 20.51% | -56.20% |
| 2020 | 46.83% | 125.47% |
| 2019 | 20.77% | 37.82% |
| 2018 | 15.07% | -169.87% |
| 2017 | -21.57% | -20.20% |
| 2016 | -27.03% | -69.72% |
| 2015 | -89.28% | -601.01% |
| 2014 | 17.82% | 2,870.00% |
| 2013 | 0.60% | -98.55% |
| 2012 | 41.43% | -17.52% |
| 2011 | 50.23% | 1.89% |
| 2010 | 49.30% | 32.21% |
| 2009 | 37.29% | 95.24% |
| 2008 | 19.10% | 338.07% |
| 2007 | 4.36% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 19.41% | -96.86% |
DE
|
|
| 19.68% | -96.82% |
DE
|
|
| 10.52% | -98.30% |
JP
|
|
| 17.08% | -97.24% |
CH
|
|
| 22.93% | -96.30% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.